RxDoctor Payments Data

Ricky Bowlin, MD

Internal Medicine · Greenville, OHNPI 1699727461

Payments from drug & device makers

$186in general payments, 2019–2025

Across 13 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$64
  • Novartis$27
  • GSK$23
  • Sanofi-aventis U.S. LLC$17
  • Teva Pharmaceuticals USA, Inc.$15
  • Johnson & Johnson$14
  • plus $24 from 2 others

What the payments were for

  • Food & beverage$186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$186 in reported general payments places this provider in the 50th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$2,827
Medicare patients
76
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$72,407
OzempicSemaglutide62$68,912
JardianceEmpagliflozin42$32,565
FarxigaDapagliflozin Propanediol24$23,402
XareltoRivaroxaban11$16,988
TrulicityDulaglutide15$15,575
JanuviaSitagliptin Phosphate14$13,265
Breo ElliptaFluticasone/Vilanterol12$10,877
PremarinEstrogens, Conjugated13$7,716
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,540
Potassium Chloride84$5,175
Levothyroxine Sodium407$2,751
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,449
ShingrixVaricella-Zoster Ge/As01b/Pf11$2,213
Atorvastatin Calcium281$2,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$13$68,91262 claims
Boehringer IngelheimJardiance$11$32,56542 claims
AstraZenecaFarxiga$64$23,40224 claims
Johnson & JohnsonXarelto$14$16,98811 claims
GSKBreo Ellipta, Shingrix$23$13,08923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Greenville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →